hotspot -WSS

hotspot

author：fashion 2025-09-27 12:56:26 - browse：843

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental Alzheimer’s drug donanemab ahead of a panel of outside experts that it is convening on Monday:

Should the patients who receive the medicine be limited based on PET scans of a protein called tau that Eli Lilly used as a key criteria for trying to determine whether they should receive the drug? That could reduce usage of the medicine by adding a barrier to its use.

And how do the potential risks of using the drug compare to its benefits? The FDA points to one analysis, admittedly with missing data, that could indicate patients who receive the drug have a higher risk of dying.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Weight loss drug costs may need more research, senator suggests

WSS

CRISPR pioneers react to Casgevy, first gene

PBM reforms clear House panel

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Readout LOUD podcast: A CRISPR milestone, biotech mixology

A strong 6.5

explore

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

ChatGPT in medicine: STAT answers readers' burning questions

Gain of function research would be limited under House proposal

As demand for Covid shots wanes, Moderna seeks its next success

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Walensky prepares to leave CDC — and Congress — behind

CRISPR pioneers react to Casgevy, first gene

Hepatitis C has a cure — but many Americans still lack access to it

BridgeBio heart drug succeeds in pivotal study

What does generative AI mean for health care? We asked experts

NYU radiologists take on the challenge of expensive MRI machines

Wikipedia

Johnson & Johnson sues to stop Medicare negotiation

Biden administration sends mixed signals on US soldier who crossed into North Korea

UK homeowners get some respite as inflation falls by more than anticipated to a 15

Israeli protesters block highways, train stations as Netanyahu moves ahead with judicial overhaul

Lack of darker skin in textbooks, journals harms patients of color

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

leisure time

Wikipedia

focus

leisure time